The #1 Prescribed biologic Among Allergists and ENTs3

>800,000 PATIENTS TREATED WITH
DUPIXENT WORLDWIDE ACROSS 5
INDICATIONS1,4,a

Explore the efficacy and safety

aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France,
Germany, Italy, Japan, the Netherlands, Spain, UK, and US), representing ~90% of patients. Data through December 2023.4

WITH DUPIXENT, AIM TO BREAK THE CYCLE OF RECURRENCE
IN CRSwNP DUE TO CHRONIC TYPE 2 INFLAMMATION1,2,5-7:

TARGET
SOURCES OF
TYPE 2 INFLAMMATION
  • DUPIXENT targets IL-4 and IL-13 signaling, key and central drivers of underlying type 2 inflammation and its disease burdens1,8,9,b

bThe mechanism of dupilumab action has not been definitively established.1

TREAT
SYMPTOMS
  • Rapid results at Day 3 for Loss of Smellc and Day 2 for nasal congestion10,d

Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.10,11

  • Sustained results through Week 521,2,e,h
MAINTAIN
CONTROL
  • 83% fewer patients required surgery, including revision surgery1
  • 74% fewer patients required systemic steroids1

76% fewer patients required surgery and/or systemic steroids.1 Individually, these were not multiplicity-adjusted endpoints.1,2

 

cLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02). Patient-reported outcome.10-12

dLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).10,12

eLoS at Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (P<0.0001).2

fNC at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (P<0.0001).1,2

gLoS at Week 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.10 (95% CI: -1.31, -0.89).1,2

hNC at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (P<0.0001).2

Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.1

Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.1

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

DUPIXENT MyWay® Logo

Support can make all the difference. DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

DUPIXENT MyWay
ENROLLMENT FORMS

English Enrollment Form
Spanish Enrollment Form

Check Formulary Status in Your Area

See the coverage status for DUPIXENT, prior authorization, and step edit information by ZIP code.